VastProTech and Silexon Conduct Cooperation in Innovative Drug Development Projects

On December 9, 2021, Silexon CEO Mr. Hainian Zeng, BD VP Mrs. Yanhong Zhang, and Supervisor of Business Development Mr. Hua Zhu, together, visited VastProTech. Mr. Hainian Zeng and Dr. Wenfeng Zhu briefed basic situations on both sides and found the two sides’ technical superiorities and complementary points. They decided to probe the possibility of employing their strong capabilities along the innovative drug development industry chain for joint-force novel drug development projects. The two parties will cooperate in selected innovative drug development projects, which are based on elderly patient diseases, specific disease targets and indications of the nervous system and immune system, and based on natural compounds with basic therapeutic efficacy. VastProTech and Silexon have already signed a framework cooperation agreement on November 12, 2021. According to this agreement, the two companies agreed to take advantage of both parties' technical advantage and manufacturing capability to promote and accelerate innovative drug development projects.

Silexon is founded in September 2018, supported by the Turing Artificial Intelligence Research Institute. Silexon is an AI-based biotechnology company, using artificial intelligence algorithms to discover disease targets and new indications for drugs, Improve the screening efficiency of first in class and fast follow new drugs, drug-like prediction, MHC epitope prediction, RNA optimization, and accelerate the production of large molecules.

Silexon has got over a hundred million yuan in its A round of financing, led by Sequoia China and Eight Roads joint investment, with participation from Quan Capital. MSA Capital, the lead investor in the previous round, once again increased. Silexon become a company among the new generation AI-driven platform technology companies in the AI+ pharmaceutical track, which is jointly invested by several first-line biomedicine and TMT funds.